Ferdinand Groenewald
About Ferdinand Groenewald
Ferdinand Groenewald is BioSig Technologies’ interim Chief Financial Officer and Principal Accounting Officer, appointed June 5, 2024; he was age 40 as of November 5, 2024 and holds a Bachelor of Science in Accounting from the University of South Africa . He is a certified public accountant with extensive finance and accounting experience, including current service as Vice President, Finance at Alaunos Therapeutics, Inc. (since February 2024) . Company compensation philosophy emphasizes pay-for-performance and equity alignment, but the proxy does not disclose company TSR, revenue growth, or EBITDA performance tied specifically to Mr. Groenewald .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Muscle Maker, Inc. | CFO | Sep 2018 – Jan 2022 | Not disclosed |
| Muscle Maker, Inc. | Chief Accounting Officer | Jan 2022 – Jul 2022 | Not disclosed |
| Muscle Maker, Inc.; Muscle Maker Development LLC; Muscle Maker Corp., LLC | VP Finance; PFO; PAO | Jan 2018 – May 2018 | Not disclosed |
| Sadot Group, Inc. | Controller; VP-Finance & Accounting; CFO | Not dated | Not disclosed |
| Wrinkle, Gardner & Co. PC | Accountant | Not dated | Not disclosed |
| Financial Consulting Strategies LLC | Senior Staff Accountant | Not dated | Not disclosed |
| Alaunos Therapeutics, Inc. | VP Finance | Feb 2024 – present | Not disclosed |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| HeartCore Enterprises, Inc. (Nasdaq) | Independent Director | Jan 24, 2022 – present | Not disclosed |
| SYLA Technologies Co., Ltd. (Nasdaq) | Independent Outside Director | Dec 1, 2022 – present | Not disclosed |
| Sushi Ginza Onodera, Inc. | Independent Director | Jul 1, 2023 – May 7, 2024 | Not disclosed |
Fixed Compensation
| Component | Amount | Terms | Effective Date |
|---|---|---|---|
| Consulting fee (Interim CFO) | $15,000 per month | Agreement continues indefinitely; terminable by either party with 30 days’ notice; standard indemnification | Jun 5, 2024 |
Performance Compensation
- No individual performance awards, target bonus, or payout metrics specific to Mr. Groenewald are disclosed in the proxy or 8-Ks. Company’s 2023 Long-Term Incentive Plan permits performance awards based on financial and strategic criteria, but award-level details for Mr. Groenewald are not provided .
Equity Ownership & Alignment
| As-of Date | Shares Beneficially Owned | Ownership % of Common | Instrument Detail | Hedging/Pledging |
|---|---|---|---|---|
| Jul 22, 2025 | 235,000 | <1% | Comprised of shares of Common Stock | Company policy prohibits hedging and pledging by officers/directors/employees |
- Stock ownership guidelines for executives are not disclosed in the cited materials .
- Vested vs. unvested breakdown, options, RSUs, or pledges specific to Mr. Groenewald are not disclosed; footnote indicates the holding is common stock, with no options/RSUs footnoted for him .
Employment Terms
- Appointment: Interim Chief Financial Officer, Principal Accounting Officer, and VP Finance effective June 5, 2024 .
- Agreement: Consulting arrangement at $15,000/month; indefinite term; terminable on 30 days’ notice by either party; reimbursement of customary business expenses; Company indemnification on customary officer terms .
- Severance/Change-of-Control: No executive-specific severance or change-of-control provisions disclosed for Mr. Groenewald. Company-level equity plan includes standard change-in-control mechanics and recoupment/clawback for restatements, but individual agreements for Mr. Groenewald are not disclosed .
Investment Implications
- Alignment: Direct ownership of 235,000 common shares aligns interests; policy prohibiting hedging/pledging supports long-term alignment and reduces governance risk .
- Retention Risk: Consulting agreement structure (indefinite term, 30-day termination notice) implies flexibility and potential transition risk versus fixed-term executive contracts .
- Pay-for-Performance Visibility: The company’s incentive plan permits robust performance-based awards, but the absence of disclosed individual metrics or equity grants for Mr. Groenewald limits pay-for-performance analysis at the executive level .
- Governance Safeguards: Presence of clawback policy tied to restatements and explicit anti-hedging/pledging policy are positive governance signals; however, no detailed ownership guideline compliance data is provided .